Lymphoma
From pathogenesis to management — classification, presentation, staging, and immunotherapy.
These slides are an outline only. Read the accompanying material with them: the notes under each slide below, and the Hematology Handbook chapters on Hodgkin lymphoma, non-Hodgkin lymphoma and T-cell lymphomas. Then work through the Internal Medicine Casebook and the Hematology Question Bank.

What this lecture is about
These slides are an outline only. Read the accompanying material with them: the notes under each slide on this page, and the Hematology Handbook chapters on chronic lymphocytic leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma and T-cell lymphomas. Then work through the Internal Medicine Casebook and the Hematology Question Bank.
Lymphoma is a malignancy of lymphocytes, and it is the great mimic of clinical medicine: it can present as a lump in the neck, as a fever of unknown origin, as a bowel obstruction, as a rash, or as a neurological syndrome. This lecture is built to give you a framework for recognising it and a discipline for confirming it.
The subtitle names the four sections. Physiology first, because every lymphoma is a normal lymphocyte frozen at one stage of its development, and the classification only makes sense once you know those stages. Classification next, using the WHO system and the anatomy of the lymph node. Diagnosis third: the presentation, the examination, the emergencies, and a case that shows why the right biopsy matters. Immunotherapy last, because the treatment of lymphoma is where antibodies against surface markers first changed the practice of oncology.
The cell on the title slide is a lymphocyte, its surface covered in the projections that carry the receptors you will meet on the next slide.

The defenders: three kinds of lymphocyte
The immune system's adaptive arm is built from three lymphocyte populations, and lymphomas are classified by which of them the malignant cell resembles. B cells are responsible for humoral immunity: they make antibody and they present antigen to T cells. T cells provide cell-mediated immunity, in two flavours: cytotoxic T cells that kill infected or malignant cells directly, and helper T cells that regulate the response. NK cells, natural killers, belong to innate immunity and mount a rapid response to virus-infected and tumour cells without needing prior sensitisation.
Look at the surface markers drawn on the T cell: the T-cell receptor, CD3, CD4 and CD8, CD2 and CD28. These CD molecules are the labels by which a pathologist identifies a lymphocyte's lineage, using the technique of immunophenotyping. When a biopsy is reported as a T-cell or B-cell lymphoma, this is how the decision was made, and later in the lecture a treatment will be aimed at one of these markers.
All three lineages arise from hematopoietic stem cells in the bone marrow. B cells complete their maturation there; T cells migrate to the thymus to mature, which is where their name comes from.

The journey of a B cell: three compartments, three sets of markers
This slide is the key to the whole classification, so follow it from left to right. A B cell passes through three anatomical compartments during its life, and at each stage it wears a different set of surface markers.
In the bone marrow it develops from a stem cell through the pro-B and pre-B stages to an immature B cell, carrying CD10 and CD19. It then enters the peripheral blood as a naive B cell, displaying surface IgM and IgD and now expressing CD20. When it meets its antigen it enters the germinal centre of a lymph node, where it proliferates as a centroblast, matures into a centrocyte, and leaves as either a plasma cell, which secretes antibody and carries CD38 and CD138, or a long-lived memory B cell.
Every station on this timeline has a malignant counterpart. A tumour of the marrow stage is a lymphoblastic leukemia or lymphoma, the precursor neoplasm of slide 5. Tumours of the mature CD20-positive stages are the common B-cell lymphomas, and CD20 is the target of the antibody on slide 17. A tumour of the plasma cell, CD138 positive, is myeloma, which has its own lecture. Slide 6 will map the germinal centre stages onto specific lymphomas.

Pathogenesis: what turns a lymphocyte malignant
The left column lists the conditions under which lymphoma arises, and they share a theme: a lymphocyte population that is being driven to proliferate for a long time, or that has lost its normal supervision. Chronic infection, viral or bacterial, keeps lymphocytes dividing in response to persistent antigen. Immunodeficiency, for example after transplantation, removes the surveillance that would otherwise eliminate an abnormal clone, and autoimmune diseases such as lupus and rheumatoid arthritis provide both chronic stimulation and, through their treatment with immunosuppressant medications, reduced surveillance.
The right column names the genetic lesions, and three translocations are worth memorising because each defines a lymphoma. In t(11;14) the cyclin D1 gene is moved next to a highly active immunoglobulin gene and drives the cell cycle: this is mantle cell lymphoma. In t(14;18) the BCL2 gene is overexpressed; BCL2 blocks apoptosis, so the cells fail to die: this is follicular lymphoma. In t(8;14) the MYC oncogene is overexpressed and drives relentless proliferation: this is Burkitt lymphoma.
Notice that chromosome 14 appears in all three. It carries the immunoglobulin heavy chain locus, which is switched on at full power in every B cell, and whatever gene is translocated beside it is switched on with it. Each translocation gives a different defect, failing to stop dividing, failing to die, or dividing too fast, and the resulting lymphomas behave differently in the clinic as a result.
See it online.
- Mantle cell lymphoma, the t(11;14) lymphoma ASH Image Bank
- Follicular lymphoma, the t(14;18) lymphoma ASH Image Bank
- The starry-sky pattern of Burkitt lymphoma, the t(8;14) lymphoma ASH Image Bank

The WHO classification: four families
The WHO system classifies lymphoid neoplasms by the cell they derive from and its stage of maturity, not by where in the body they happen to appear. The diagram groups them into four families.
Mature B-cell neoplasms are the largest family and contain most of the lymphomas you will see: chronic lymphocytic leukemia and its tissue form small lymphocytic lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, Burkitt lymphoma and mantle cell lymphoma. Three of these you have just met by their translocations. Mature T- and NK-cell neoplasms are less common and include mycosis fungoides, a lymphoma of the skin, peripheral T-cell lymphoma and anaplastic large cell lymphoma. Hodgkin lymphoma stands as its own family because of its distinctive biology, histology and treatment; nodular sclerosis and mixed cellularity are its two commonest subtypes. Precursor neoplasms are tumours of immature lymphoblasts, and the same disease is called lymphoblastic leukemia when it is in the marrow and blood and lymphoblastic lymphoma when it forms a mass.
You are not expected to know every entity. You are expected to know the four families, to be able to place the common named lymphomas within them, and to understand that the name on the pathology report determines the treatment. That is why the biopsy, on slide 13, has to be done properly. The next slide explains why some of these entities are called leukemias and others lymphomas.
Read next. Case 55 · The Chronic Leukaemias in the casebook, in its section on chronic lymphocytic leukaemia, follows the first entity on this slide in one patient: a well woman with a high lymphocyte count, diagnosed on blood flow cytometry by CD5, CD19 and CD23 together. It also teaches watch and wait as a treatment decision, and Richter transformation, where fast-growing nodes and a rising LDH call for an urgent biopsy.
See it online.
- Reed-Sternberg cells in nodular sclerosis Hodgkin lymphoma ASH Image Bank

Leukemia or lymphoma: why one disease can carry two names
Students meet leukemia and lymphoma as two chapters, and then find CLL on the previous slide listed among the lymphomas. The confusion comes from the words, which are older than the classification. Leukemia means “white blood”, and names the disease from what is seen in the blood. Lymphoma names it from the lump.
The WHO and the International Consensus Classification (ICC) start somewhere else. They sort lymphoid neoplasms by lineage, B cell or T/NK cell, and by maturity, precursor or mature; the WHO 5th edition lists them in that order. Where the clone sits is not the first question. So the place changes the name, not the disease. A clone that lives mainly in blood and marrow is called a leukemia. The same kind of clone growing mainly as a mass in a node or another tissue is called a lymphoma. Many patients have both, and many WHO entities simply carry both names. One honest caveat: for the T- and NK-cell neoplasms, WHO also uses the site of disease to group some families, such as the lymphomas of the skin. The rule is the starting point, not the whole story.
The examples. CLL and SLL are one disease. The iwCLL guidelines describe CLL, following WHO, as a lymphoma that can only be told apart from SLL by its presence in the blood. CLL needs at least 5×109/L B cells in the blood; SLL is the same cell in the nodes, with fewer than that in the blood. Lymphoblastic leukemia and lymphoblastic lymphoma, of B or T cells, are one entity in both WHO and ICC. It is called leukemia when blasts fill the marrow and blood, and lymphoma when a mass leads, for example a mediastinal mass in a teenager with T-cell disease. The proportion of marrow blasts that separates the two names is an agreed convention, not a biological boundary. Mantle cell lymphoma usually lives in the nodes, but WHO now lists a separate leukemic non-nodal form. It is found in blood, marrow and spleen with little or no lymph node enlargement, it is often without symptoms, and it has a better outcome than classic mantle cell lymphoma.
Mycosis fungoides is a lymphoma of the skin that moves slowly through patches, plaques and tumors. Sézary syndrome adds red skin all over (erythroderma), enlarged nodes and Sézary cells in the blood. The two are related, and Sézary syndrome is often taught as the leukemic form of mycosis fungoides, but WHO and ICC now list them as two separate entities. Hairy cell leukemia keeps its old name, yet WHO places it in one family with the splenic B-cell lymphomas. Adult T-cell leukemia/lymphoma, caused by the virus HTLV-1, puts both words in its title.
Why it matters. The name tells you the cell, and the cell decides the treatment. CLL and SLL are treated the same way, whatever the name on the report. The place does change one thing: the test. A disease that circulates can be diagnosed from a blood sample by flow cytometry. A disease that sits in a node needs the node, which is the point of slide 13. CLL, on slides 15 and 16, shows the first route.

Anatomy of a malignancy: where in the follicle each lymphoma is born
The cross-section shows a single lymphoid follicle in a lymph node, and it is the anatomical version of the timeline on slide 3. The follicle has a pale follicle centre, the germinal centre where B cells that have met antigen proliferate and mature, surrounded by a darker mantle zone of naive B cells that have not yet been stimulated.
Each zone gives rise to the lymphomas that resemble its normal occupants. A tumour of mantle zone cells is mantle cell lymphoma. Tumours of germinal centre cells include follicular lymphoma, which recreates the follicle architecture, Burkitt lymphoma and many cases of diffuse large B-cell lymphoma. Cells that have completed the germinal centre reaction and are leaving it give rise to the post-germinal tumours: plasma cell myeloma, the tumour of the fully differentiated antibody-secreting cell, and MALT lymphoma, arising from the memory cells of mucosal lymphoid tissue.
The lesson is that a lymphoma is a snapshot of a normal B cell arrested at one station, and its behaviour is inherited from that station. Germinal centre cells are built to proliferate fast, and Burkitt lymphoma is one of the fastest-growing human tumours. Memory cells are built to persist quietly, and follicular and MALT lymphomas tend to be indolent.

Clinical presentation: the great mimicker
Lymphoma has no single presentation, which is why the slide draws its manifestations across a whole body. The commonest is the painless, rubbery lymph node: enlarged, firm but not hard, mobile and not tender, unlike the tender nodes of infection. But many patients never notice a node.
The B symptoms are systemic and are recorded in staging because they carry prognostic weight: unexplained fever, drenching night sweats that soak the bedclothes, and loss of more than 10 percent of body weight. Ask about them specifically, because patients rarely volunteer sweats.
Extranodal disease presents in the organ involved. Lymphoma of the gut can present as an abdominal mass or as an obstruction. Lymphoma of the skin, mycosis fungoides, presents as a chronic rash that may be treated for years as eczema or psoriasis before a biopsy is taken. Add to these the paraneoplastic syndromes on slide 10 and you see why a lymphoma should be on the differential of almost any persistent, unexplained illness.
See it online.
- Mycosis fungoides on a skin biopsy ASH Image Bank

Examination: every station, and the two organs
The lymphatic system is drawn over the body to remind you that examination for lymphoma is a systematic tour of the nodal stations, not a glance at the neck. Each region drains a territory, so the site of an enlarged node points to where a primary process might be.
The cervical and supraclavicular nodes are the most important. A supraclavicular node, especially the left-sided Virchow's node, drains the thoracic duct and carries a high risk of malignancy in the chest or abdomen; it should never be dismissed. The axillary and epitrochlear nodes drain the arm; an epitrochlear node above the elbow is unusual and worth noting. The inguinal nodes drain the lower limb and are so often mildly enlarged from minor infections of the leg that they carry the least weight.
Two organs complete the examination. Palpate for the spleen and liver, because lymphoma commonly involves both, and organomegaly may be the only physical sign when the disease is internal, as it was in the case on slide 12. Describe every node you find by site, size, consistency, tenderness and mobility.

Paraneoplastic syndromes: when the lymphoma announces itself from a distance
A paraneoplastic syndrome is an illness caused not by the tumour's bulk but by the immune response it provokes, typically an antibody that cross-reacts with normal tissue. The table lists four that are associated with lymphoma, and each may appear before the lymphoma itself is evident.
Two are neurological and both are linked to Hodgkin lymphoma. Limbic encephalitis presents with memory loss and confusion; in association with Hodgkin lymphoma it is called Ophelia syndrome and is mediated by antibodies against the mGluR5 receptor. Cerebellar degeneration presents with ataxia and loss of balance, mediated by the anti-Tr antibody. Myasthenia gravis, with fatigable muscle weakness, is classically associated with thymoma but also occurs with lymphoma. Dermatomyositis, a rash with proximal muscle weakness, is associated with non-Hodgkin lymphoma among other cancers.
The practical message is that an unexplained subacute neurological or dermatological syndrome in an adult should prompt a search for an occult malignancy, and lymphoma is high on that list. Treating the lymphoma is usually the only effective treatment of the syndrome.

Tumor lysis syndrome: the emergency of a tumour that dies too fast
Lymphoma cells that divide rapidly also die rapidly, especially in the first days after chemotherapy begins, and when a large mass of cells breaks open at once their contents overwhelm the kidneys. The result is tumor lysis syndrome, and the slide organises its four derangements with the mnemonic PUCK.
P: hyperphosphatemia. Dying cells release phosphate, which binds calcium and precipitates as calcium phosphate in the tissues and renal tubules. U: hyperuricemia. Nucleic acids from the broken cells are metabolised to uric acid, which crystallises in the tubules and causes renal failure. C: hypocalcemia, the one arrow pointing down, because the calcium has been consumed by the phosphate; it causes tetany and seizures. K: hyperkalemia. Potassium, the main intracellular cation, floods the plasma and causes arrhythmias, which is the immediately fatal part of the syndrome.
Management is mostly prevention in patients known to be at risk. Aggressive intravenous hydration keeps the tubules flushed. Allopurinol blocks the enzyme that produces uric acid, preventing further accumulation. Rasburicase breaks down uric acid that has already formed and is used in high-risk patients. Electrolytes are monitored closely and potassium is treated as it rises. The same syndrome appears in the acute leukemia lecture; it is a hazard of any rapidly proliferating hematological malignancy.

Case study: a 22-year-old woman with a positive ANA
The case is chosen because it is a trap. A young woman has eight months of fatigue, weight loss and pain in the knees, and she has been losing her hair. On examination the liver and spleen are enlarged, but there are no palpable lymph nodes. Her blood shows a low white cell count, a normocytic anemia, a high lactate dehydrogenase and a positive antinuclear antibody.
Read the story one way and it is systemic lupus erythematosus: a young woman, joint pain, hair loss, cytopenias, and a positive ANA. Most clinicians would reach for that diagnosis. But two findings do not fit comfortably. Organomegaly of this degree is unusual in lupus, and a high LDH signals rapid cell turnover, which is the signature of a proliferating tumour rather than an autoimmune disease.
The dilemma teaches two things. First, a positive ANA is not specific: it occurs in healthy people, in infections and in malignancy, and it should confirm a clinical picture rather than create one. Second, when a patient has weight loss, organomegaly, cytopenias and a raised LDH, malignancy must be excluded with tissue, however plausible the alternative. The next slide is about how that tissue should be obtained.

Tissue is the issue: why the wrong biopsy gives the wrong answer
The diagnosis of lymphoma is made under a microscope, and the slide contrasts the two ways of getting the tissue there. The contrast is the single most important practical lesson in the lecture.
Fine needle aspiration draws cells out of a node through a needle. It yields cytology, individual cells in suspension, and it destroys the one thing the pathologist most needs: the architecture of the node. Whether the follicles are preserved, effaced or replaced by sheets of cells, whether the pattern is nodular or diffuse, is what separates a reactive node from a lymphoma and one lymphoma from another. Without it the report often reads "reactive lymphoid proliferation", which in a patient who actually has lymphoma is a false negative, and a dangerous one because it reassures.
Excisional biopsy, removing the whole node intact, is the gold standard. It preserves the architecture, gives enough tissue for immunophenotyping and genetic studies, and allows an accurate WHO classification, which is what the treatment depends on. When lymphoma is a serious possibility, ask for an excisional biopsy of the most accessible abnormal node, and do not accept a negative needle aspirate as an answer.
Read next. Case 56 · Lymphoma in the casebook is this slide in one patient: a young woman with a rubbery node in the neck and night sweats. Its most important investigation is the one on this slide, an excision biopsy and not a needle aspirate. It adds a second rule: do not give steroids before the biopsy, because they can kill lymphoma cells and leave the histology impossible to read.

Staging and imaging, and how the case resolved
Once lymphoma is diagnosed, treatment depends on how far it has spread, and staging is done by imaging. PET/CT combines a metabolic scan with anatomical CT: lymphoma cells take up glucose avidly because they are dividing quickly, so active disease lights up as hot spots wherever it is, including in nodes of normal size and in organs that look normal on CT alone. Conventional CT measures the size of nodes and the involvement of organs, in particular the liver and spleen highlighted on the illustration.
The case from slide 12 resolves here. Imaging showed aggressive, widespread disease despite the initial biopsy having been reported as reactive. That sequence, a reassuring needle biopsy followed by imaging that revealed the truth, is exactly the failure mode the previous slide warned about. When the clinical picture and the biopsy disagree, believe the clinical picture and obtain better tissue.
Imaging also gives a baseline. The same scan repeated after treatment shows whether the hot spots have gone, which is how response is judged.
See it online.

CLL up close: presentation and diagnosis
The previous slide staged most lymphomas with PET/CT. CLL is the exception worth knowing, and it is the commonest leukemia of adults in the West. It is also the clearest case of the naming rule on slide 6: a lymphoma of small mature B cells that lives mostly in the blood. The cells look normal but do not work, and they build up slowly in blood, marrow, nodes and spleen.
Presentation. Most patients are older adults, and many feel well. The disease is often found by chance, as a high lymphocyte count on a blood count done for another reason. Others come with enlarged nodes, which are symmetrical and rubbery, an enlarged spleen, B symptoms, or repeated infections. The main problem is not the count but the immune system. The clone crowds out normal B cells, immunoglobulin levels fall, and infection is the commonest cause of death. The immune system also turns on the patient's own cells, giving warm autoimmune hemolytic anemia and immune thrombocytopenia. The film shows many small mature lymphocytes and smudge cells: fragile lymphocytes that break when the film is spread.
Diagnosis. The job is to prove that the lymphocytes are one clone of B cells with the CLL pattern, and this is done on blood. The international workshop on CLL (iwCLL 2018) sets the rules. The B-cell count in the blood must be at least 5×109/L, sustained for at least 3 months. Flow cytometry then shows the clone. The cells carry CD5 together with the B-cell markers CD19, CD20 and CD23, with weak surface immunoglobulin and weak CD20. CD5 is normally a T-cell marker, so CD5 on a B cell is the clue. Every cell makes only one light chain, kappa or lambda. That light-chain restriction is what proves the cells are a clone and not a reaction. A marrow examination is generally not needed for the diagnosis; it is kept for cytopenias whose cause is unclear. Patients often expect one, and it is worth telling them they may not need it.
The figure of 5×109/L is an agreed cut-off, not a natural boundary. Below it, the same cells are given other names. If the nodes are enlarged, the disease is SLL, and the diagnosis should be confirmed on a lymph node biopsy. If there are no enlarged nodes or organs, no cytopenias and no symptoms, it is monoclonal B-cell lymphocytosis (MBL).
Read next. Case 55 · The Chronic Leukaemias in the casebook follows this slide in one patient: a well woman with a high lymphocyte count, diagnosed on blood flow cytometry. The Hematology Handbook chapter on chronic lymphocytic leukemia covers the same ground in more depth.

CLL up close: staging and treatment
The previous slide proved the clone. This slide decides what to do about it, and in early CLL the answer is often nothing yet.
Staging. Unlike the lymphomas on slide 14, CLL is staged at the bedside. iwCLL 2018 accepts two systems, and both use only the examination and the blood count, with no imaging. Binet counts enlarged areas: head and neck, armpits, groins, spleen and liver. Each node area counts once, whether one side or both is involved. Stage A has two areas or fewer, and stage B three or more, both with hemoglobin of at least 100 g/L and platelets of at least 100×109/L. Stage C is hemoglobin below 100 g/L or platelets below 100×109/L, whatever the nodes. Rai is now used in a modified three-group form: low risk is lymphocytosis alone; intermediate risk adds enlarged nodes, spleen or liver; high risk is anemia or platelets below 100×109/L. Both systems rest on one idea: disease that has filled the marrow enough to cause anemia or low platelets is advanced.
Watch and wait. In early disease without symptoms, treatment does not make people live longer, so the right management is to watch. iwCLL extends this to intermediate-risk disease, Binet B, until the disease becomes active. Watching is a decision, not neglect, and it has to be explained, ideally in writing, with the signs that would change it. iwCLL lists what makes the disease active: marrow failure with hemoglobin below 100 g/L or platelets below 100×109/L; a spleen at least 6 cm below the left costal margin, or one that is growing or causing symptoms; nodes at least 10 cm across, or nodes that are growing or causing symptoms; a lymphocyte count that rises by 50 percent or more in 2 months, or doubles in under 6 months; autoimmune anemia or thrombocytopenia that responds poorly to steroids; symptomatic disease outside the nodes; and disease-related symptoms (weight loss of 10 percent or more in 6 months, fatigue bad enough to stop the patient working (ECOG 2 or worse), fever of 38.0 °C or more for 2 weeks without infection, or night sweats for more than a month without infection). The lymphocyte count alone is not a reason to treat, and neither are low immunoglobulins alone. These cut-offs are agreed conventions.
Before treatment. Test for TP53 mutation and deletion 17p before every line of treatment, because new genetic changes can appear as the disease goes on. They change the choice: iwCLL advises that patients with TP53 abnormalities should not receive chemotherapy if other options exist. IGHV mutation status is also checked before treatment; it helps predict the outcome and guide the choice of drug.
Treatment. Modern CLL treatment is targeted rather than cytotoxic. The main drugs are the Bruton tyrosine kinase (BTK) inhibitors and the BCL2 inhibitor venetoclax, with or without an anti-CD20 antibody, the target you will meet on the next slide. Venetoclax carries a real risk of tumor lysis syndrome (slide 11), so it is started with a slow dose ramp and close monitoring. Supportive care matters as much. Vaccinate, avoiding live vaccines, ideally before treatment starts; iwCLL notes that no randomized trial has yet shown that vaccination lowers infection rates in CLL, so this is advice from experience rather than trial evidence. Keep a low threshold for treating infection, give immunoglobulin replacement when infections keep coming back, use steroids for autoimmune cytopenias, and check the skin, because second cancers, skin cancer above all, are more common.
Richter transformation. In a few patients CLL turns into an aggressive large B-cell lymphoma. Think of it when one node grows fast, with fever and a rising LDH. It needs an urgent biopsy, and here PET has a use: iwCLL notes that PET is not useful in CLL except when Richter transformation is suspected, where it shows the best node to biopsy. This brings back the lesson of slide 13: when a lymphoma changes, the tissue decides.
Read next. Case 55 · The Chronic Leukaemias makes one point about watch and wait that this slide can only state: a patient told they have leukemia and that nothing will be done hears neglect. It shows how to explain the decision, and what would trigger treatment.

Treatment: four pillars, and the antibody that changed lymphoma
The diagram shows the idea that transformed the treatment of B-cell lymphoma. Rituximab is a monoclonal antibody engineered to bind CD20, the surface marker you saw appear on the naive B cell on slide 3. Once bound, it flags the cell for destruction by the patient's own immune effector cells and complement. Because CD20 is present on mature B cells but not on stem cells, precursors or plasma cells, the antibody removes the malignant B cells and their normal counterparts while sparing everything else, and normal B cells regenerate afterwards from the CD20-negative precursors.
Rituximab is one of four pillars. Chemotherapy, most often the CHOP combination, remains the backbone for aggressive lymphomas. Radiotherapy treats localised disease and bulky sites. Immunotherapy with anti-CD20 antibody is added to chemotherapy for CD20-positive B-cell lymphomas. Targeted molecular therapy attacks the specific signalling pathways that particular lymphomas depend on.
Which pillars are used, and in what combination, depends entirely on the histological subtype, which closes the loop back to the biopsy. A lymphoma that has been classified correctly can be treated precisely; one that has not cannot.
See it online.

Five things to take away
Definition. Lymphoma is a malignancy of mature lymphocytes arising in lymph nodes or in extranodal tissue. It is classified by the normal cell and developmental stage it resembles, and the WHO system groups it into four families.
Pathogenesis. It is driven by genetic translocations, of which t(14;18) and BCL2 in follicular lymphoma is the archetype, arising on a background of chronic antigenic stimulation or immune dysregulation.
Diagnosis. Lymphoma is the great mimicker, presenting through nodes, B symptoms, organs, skin or paraneoplastic syndromes. Excisional biopsy is mandatory, because only an intact node shows the architecture on which classification depends.
Emergency. Watch for tumor lysis syndrome, above all the hyperkalemia and hyperuricemia, in any patient with a rapidly proliferating lymphoma, especially in the first days of treatment.
Treatment. Accurate histological classification is what makes targeted immunotherapy possible; anti-CD20 antibody is the model, and it works because the pathologist first identified the marker on the cell.